The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 30, 2023
Filed:
May. 16, 2016
Applicant:
Medrx Co., Ltd, Higashikagawa, JP;
Inventor:
Keiko Yamasaki, Higashikagawa, JP;
Assignee:
MEDRX CO., LTD., Kagawa, JP;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 8/42 (2006.01); A61K 31/164 (2006.01); A61K 31/165 (2006.01); A61K 31/404 (2006.01); A61K 31/4164 (2006.01); A61K 9/70 (2006.01); A61K 8/49 (2006.01); A61K 9/06 (2006.01); A61Q 19/00 (2006.01); A61K 8/02 (2006.01); A61P 17/00 (2006.01); A61K 8/44 (2006.01); A61Q 19/08 (2006.01); A61K 47/24 (2006.01); A61K 31/55 (2006.01); A61K 47/10 (2017.01); A61K 9/10 (2006.01); A61K 47/18 (2017.01); A61K 9/00 (2006.01); A61K 31/343 (2006.01); A61K 31/135 (2006.01); A61K 31/405 (2006.01); A61K 31/445 (2006.01); A61K 31/4196 (2006.01); A61K 31/13 (2006.01); A61K 31/473 (2006.01);
U.S. Cl.
CPC ...
A61K 47/24 (2013.01); A61K 9/0014 (2013.01); A61K 9/10 (2013.01); A61K 9/7069 (2013.01); A61K 31/13 (2013.01); A61K 31/135 (2013.01); A61K 31/343 (2013.01); A61K 31/405 (2013.01); A61K 31/4196 (2013.01); A61K 31/445 (2013.01); A61K 31/473 (2013.01); A61K 31/55 (2013.01); A61K 47/10 (2013.01); A61K 47/18 (2013.01);
Abstract
Disclosed is a transdermal absorptive liquid preparation in which a medicament or a salt thereof is colloidally dispersed in propylene glycol or a propylene glycol-containing solvent, whose transdermal permeability of the medicament is excellent, problem of skin irritation is reduced. This transdermal absorptive liquid formulation has a mode of particle diameter at around 100 nm, and an average particle size of 50 to 500 nm. This transdermal absorptive liquid formulation makes marked improvement in the transdermal permeability by further containing an absorption promoter such as triethanolamine.